BMRN — BioMarin Pharmaceutical Inc.

Summary of BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $766 million for Q1 2026, up year-over-year, driven by increased demand in Enzyme Therapies and Voxzogo.
• Enzyme Therapies Revenue: Increased 6% year-over-year, with notable contributions from Vimizim, Naglazyme, and Brineura.
• Voxzogo Revenue: Strong growth in new patient starts, particularly in children under two years old.
• Non-GAAP Diluted EPS: Reported at $0.76, impacted by increased operating expenses and a $31 million charge related to manufacturing issues.
• Updated Full-Year 2026 Guidance: Total revenue guidance raised to $3.825 billion to $3.925 billion (20% growth), with Enzyme Therapies expected to generate $2.725 billion to $2.775 billion (30% growth).

2. Strategic Updates and Business Highlights

• Amicus Acquisition: Completed last week, adding Galafold and Pombility/Opfolda to BioMarin's portfolio. The integration is underway, with plans to leverage BioMarin's capabilities to enhance patient diagnosis and treatment rates.
• Regulatory Submissions: Submitted a supplemental NDA for Voxzogo's full approval and anticipates pivotal results for Voxzogo in hypochondroplasia and BMN-401 for ENPP1 deficiency in Q2.
• Commercial Strategy: Focused on driving diagnosis for Fabry disease and switching patients to new therapies for Pompe disease.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipates significant revenue growth in the second half of 2026, with over 55% of total revenues expected to be recognized in that period.
• Earnings Guidance: Non-GAAP diluted EPS guidance updated to $4.85 to $5.05, with the Amicus acquisition expected to be slightly dilutive for 2026 but accretive in 2027.

4. Bad News, Challenges, or Points of Concern

• Manufacturing Issues: A $31 million charge related to an unsuccessful manufacturing campaign impacted margins and EPS in Q1.
• Order Timing Dynamics: Revenue growth was partially offset by order timing and lower revenues from Roctavian and Kuvan.
• Competitive Pressures: The entry of competitors in the market, particularly for Voxzogo, raises concerns about patient switching and market share.

5. Notable Q&A Insights

• Integration of Amicus: Management emphasized the potential for growth through enhanced diagnosis and switching strategies for new therapies.
• Voxzogo Adoption: The company is optimistic about Voxzogo's uptake in hypochondroplasia, leveraging early diagnosis initiatives.
• ITC Hearing Update: Ongoing litigation regarding patent infringement is being closely monitored, with a decision expected in August 2026.
• BMN-333 Development: The strategy for BMN-333 involves a superiority trial to establish its efficacy over Voxzogo, with a focus on long-term growth and health outcomes.

This earnings call reflects a pivotal moment for BioMarin, with the integration of Amicus expected to significantly enhance its growth trajectory and product offerings, despite facing some operational challenges and competitive pressures.